Skip to content

Safety and efficacy of rapamycin (Sirolimus) in the treatment of PI3K-AKT1-mTOR related overgrowth syndrome

Safety and efficacy of rapamycin (Sirolimus) in the treatment of PI3K-AKT1-mTOR related overgrowth syndrome

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100042574
Enrollment
Unknown
Registered
2021-01-23
Start date
2021-04-01
Completion date
Unknown
Last updated
2021-05-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

PIK3CA related overgrowth syndrome

Interventions

affected side:use rapamycin

Sponsors

Beijing Jishuitan Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) Clinically diagnosed with Overgrowth syndrome (2) Somatic chimeric PIK3CA or AKT1 pathogenic mutations were confirmed by second-generation sequencing; (3) No limitation on gender and age; (4) No liver and kidney failure; (5) Participate in the experiment on a voluntary basis and sign the informed consent form by oneself or the legal guardian.

Exclusion criteria

Exclusion criteria: (1) Complicated with acute and chronic infections, such as fever, cough, sputum, diarrhea, vomiting, dysuria, urgency and frequency of urination, skin abscess, etc., the white blood cells were larger than the normal range, and CRP, PCT and erythrocyte sedimentation rate were increased; (2) Insufficiency of liver, kidney and bone marrow; (3) Neutrophils lower than 1.0 x 10^9/L; (4) Allergic to rapamycin; (5) Pregnant and lactating women; (6) Metabolic disorders, such as electrolyte disturbances and blood glucose abnormalities; (7) Patients with liver and lung transplantation; (8) Patients with severe hyperlipidemia; (9) Abusers of alcohol, drugs or drugs (e.g.laxatives); (10) Patients who are participating in another clinical trial that may have an impact on the purpose of this study at the same time or within one month; (11) A history of rapamycin use within a previous month; (12) Had a history of major surgery in the previous 12 weeks; (13) Had a history of live vaccination 4 weeks ago; (14) Other reasons were not considered appropriate by the researchers for clinical trials.

Design outcomes

Primary

MeasureTime frame
the circle-diameter of limb or digit;Tissue volume of the affected site;

Secondary

MeasureTime frame
Rapamycin steady-state plasma concentration;the dose of rapamycin;the score of Pediatric Quality of Life Inventory;

Countries

China

Contacts

Public ContactTian Wen

Beijing Jishuitan Hospital

wentiansyz@hotmail.com+86 13901316883

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026